Identifying a polymorphic 'switch' that influences miRNAs' regulation of a myasthenia gravis risk pathway

Lili Yang1, Jianjian Wang1, Xuesong Sun1

  • 1Department of Neurology, The Second Affiliated Hospital, Harbin Medical University, Harbin, Heilongjiang Province, China.

Plos One
|August 14, 2014
PubMed

Insights

Genetic variants and microRNAs (miRNAs) influence myasthenia gravis (MG). This study identifies miRNA-associated single nucleotide polymorphisms (miRSNPs) impacting MG pathways, revealing a novel mechanism involving genetic modulators in disease pathogenesis.

Area of Science:

  • Genetics
  • Immunology
  • Molecular Biology

Background:

  • Genetic variants and microRNA (miRNA) dysregulation are implicated in myasthenia gravis (MG) pathogenesis.
  • The role of miRNA-associated single nucleotide polymorphisms (miRSNPs) in MG remains underexplored.

Purpose of the Study:

  • To investigate the functional role of miRSNPs in MG pathogenesis.
  • To construct a network illustrating miRNA-mediated regulation of MG risk pathways and the impact of miRSNPs.

Main Methods:

  • Manual literature mining to create a catalog of 89 MG risk genes.
  • Identification of 18 MG risk pathways and 93 targeting miRNAs.
  • Integration of miRSNP database information to reveal regulatory 'switches' and construction of a miRNA-mediated SNP switching pathway network (MSSPN).

Main Results:

  • Identified 93 miRNAs targeting 18 MG risk pathways.
  • Revealed miRSNP 'switches' influencing miRNA regulation within these pathways.
  • Proposed a potential mechanism (miRSNPs→gene→pathway) for MG pathogenesis, exemplified by rs28457673 impacting the cancer pathway (hsa05200) via IGF1R.

Conclusions:

  • Genetic modulators, specifically miRSNPs, play a functional role in MG pathogenesis at a systemic level.
  • The study provides a framework for understanding miRNA and miRSNP involvement in MG.
  • Findings highlight potential therapeutic targets and diagnostic markers for MG.

Related Concept Videos

Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
41
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.6K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
20.9K
MicroRNAs01:22

MicroRNAs

9.8K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
80